The Latin America, Middle East and Africa Cervical Cancer Diagnostic Market would witness market growth of 7.6% CAGR during the forecast period (2023-2029).
Cervical cancer is the fourth most frequent cancer and the main cause of mortality for women. Large pharmaceutical corporations are actively researching the best remedies for the same. Many potential pharmaceuticals and biologics are currently undergoing clinical testing. During the forecast period, the market is expected to develop due to the introduction of technologically improved computer-guided cervical cancer screening tests designed to decrease false-negative test results and increase accuracy.
Infection with the human papillomavirus (HPV) is the primary risk factor for developing cervical cancer. The majority of infections occur as a result of sexual activity, and the majority of people recover completely without any complications after contracting the virus. More than one hundred different types of HPV have been identified. The types or strains of HPV that are most commonly associated with an increased risk of cervical cancer include HPV16 and HPV18.
A weaker immune system increases the likelihood of acquiring cervical cancer in a person. Immune suppression by corticosteroid drugs, organ donation, therapies for different types of cancer, or the human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS), can all lead to a weakened immune system. A person's immune system is less competent to combat early cancer when they have HIV Herpes. Cervical cancer is more likely to strike those with genital herpes.
According to data from the “National Hospital Registry of Cancer” (NHRC), 20% of patients with cervical and vaginal cancer and 51% of those with endometrial cancer had their condition classified as International Federation of Gynecology and Obstetrics (FIGO) stage I. Because of this, the government is making more efforts to raise awareness of these diseases and the available preventative measures. The region's rising cervical cancer incidence will spur demand for diagnostics for early diagnosis and treatment, which will fuel market expansion in LAMEA.
The Brazil market dominated the LAMEA Cervical Cancer Diagnostic Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $172.3 Million by 2029. The Argentina market is experiencing a CAGR of 8.1% during (2023 - 2029). Additionally, The UAE market would showcase a CAGR of 7.3% during (2023 - 2029).
Based on Type, the market is segmented into Pap Smear Tests, Colposcopy Tests, HPV Test, Biopsy & ECC, and Others. Based on Age Group, the market is segmented into 20 to 40 years, and Above 40 years. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Cervical Cancer Diagnostic Market is Projected to reach USD 10.2 Billion by 2029, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Becton, Dickinson and Company, Carl Zeiss AG, CooperSurgical, Inc. (The Cooper Companies, Inc.), DYSIS Medical, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., Qiagen N.V., Siemens Healthineers AG (Siemens AG) and Thermo Fisher Scientific, Inc.
By Type
By Age Group
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
